Related Experiment Video
Updated: Dec 31, 2025
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.7K
Navigating systemic therapy for metastatic castration-naïve prostate cancer
E M Kwan1,2, I A Thangasamy3,4, J Teh3
1Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia.
World Journal of Urology
|January 4, 2020
Summary
Systemic therapies, including docetaxel or AR pathway inhibitors, significantly improve outcomes for metastatic castration-naïve prostate cancer (mCNPC). Early treatment with these agents enhances patient quality of life.
Area of Science:
- Oncology
- Urology
Background:
- Advanced prostate cancer treatment has evolved significantly, particularly for metastatic castration-naïve disease.
- Recent advancements focus on systemic therapy for metastatic castration-naïve prostate cancer (mCNPC).
Purpose of the Study:
- To review evidence for systemic therapy in mCNPC.
- To provide guidance on selecting treatments to optimize patient outcomes.
Main Methods:
- Narrative review of existing and emerging evidence.
- Analysis of systemic therapy options for mCNPC.
Main Results:
- Docetaxel or AR pathway inhibitors (abiraterone, enzalutamide, apalutamide) are standard care for mCNPC with long-term ADT.
- Upfront docetaxel is now recommended for all patients, irrespective of metastatic burden.
- Treatment decisions require comprehensive patient, disease, and logistical factor assessment.
Conclusions:
- Early potent systemic therapy dramatically improves clinical outcomes in mCNPC.
- Ongoing research promises further advancements in mCNPC management and patient quality of life.
Keywords:
AbirateroneAndrogen receptor pathway inhibitorsApalutamideCastration-naïveDocetaxelEnzalutamideHormone-sensitiveMetastatic prostate cancerMore Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:56Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
02:49Cancer Therapies
9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K